STEINMAN LAWRENCE - 17 Jun 2025 Form 4/A - Amendment Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Lawrence Steinman
Issuer symbol
ATNF
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
30 Jun 2025, 17:34:53 UTC
Date Of Original Report
20 Jun 2025
Previous filing
21 Feb 2025
Next filing
18 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
STEINMAN LAWRENCE Director 3000 EL CAMINO REAL, BLDG. 4,, SUITE 200, PALO ALTO /s/ Lawrence Steinman 30 Jun 2025 0001132679

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $0 +44,959 +67% $0.000000 112,493 17 Jun 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +110,000 $0.000000 110,000 17 Jun 2025 Common Stock 110,000 $0.9290 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan (the "Equity Plan").
F2 Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.
F3 The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.

Remarks:

This Form 4/A is being filed to reflect the fact that the number of shares awarded to the Reporting Person was retroactively adjusted by the Board of Directors and Compensation Committee of the Company on June 28, 2025, so that there was sufficient room for such award, and other awards made on the same date, under the Equity Plan.